Cellectar Biosciences enters its May 8 earnings call in a radically different lending market than it sat in just 48 hours ago.
The story this week is the lending market, and it moved with extraordinary speed. Short interest exploded roughly 1,572% over the week to reach 6.5% of the free float — nearly the entire move compressed into a single session on May 5, when estimated shares short surged 1,379% in one day. Before that session, short positioning had been running well below 1% of the float for weeks, drifting quietly lower through April as the stock climbed. Then, on the same day the company published 12-month follow-up data from its Phase 2b CLOVER WaM trial showing durable responses of iopofosine I-131 in relapsed/refractory Waldenström macroglobulinemia, a fresh wave of short selling hit the tape.
The borrow market confirmed the pressure immediately. Cost to borrow had been stable between 12% and 17% APR for the entire month of April. On May 5 it jumped to 150.4% — a move of 767% in a single week. Availability has tightened to near-zero: the lending pool is almost entirely consumed, with the borrow availability at its tightest level since the 52-week peak of 100% utilization was hit. That leaves virtually no slack for anyone looking to add fresh short exposure — every share in the pool is effectively already lent out. The ORTEX short score reflected the shift instantly, vaulting from roughly 39–40 over the prior two weeks to 84.3 on May 5, placing the stock in the top percentile of the universe on short score, days-to-cover rank, and borrow tightness.
The backdrop is a stock that had already been moving. CLRB closed Tuesday at $3.18, up 12.4% on the day and 24.2% on the week, adding to a 24.7% gain over the past month. The catalyst was clear: the CLOVER WaM 12-month data impressed the market, with headlines describing durable complete and partial responses in a rare blood cancer indication. The rally attracted short sellers who appear to be fading the clinical data move ahead of the May 8 earnings call and conference presentation. The stock is now up sharply from levels where the CFO, President/CEO, and COO all bought shares on the open market back in July 2025 at $4.99 — making current price action a notable reversal of that insider cluster, even if those trades are now stale.
The lone active analyst coverage adds a constructive overlay. Maxim Group upgraded the stock to Buy in March, with a $10.00 price target — more than three times current levels. That single-analyst consensus leaves the mean target at $10.50, implying substantial upside from $3.18, though the thin coverage means any estimate-driven signal carries limited weight. The factor score on EPS surprise ranks in the 63rd percentile, suggesting the company has had a modest history of positive surprises relative to expectations. The stock's recent earnings history shows muted moves: the March print generated a 1-day gain of just 1.2% and a flat five-day drift, while the prior event produced a 3.4% day-one pop that extended to 10.4% over five sessions.
Peer performance underlines that this week's move was stock-specific, not a sector tide. Correlated names BTAI and NCNA were both slightly lower on the day on Tuesday, and ARCT and BEAM dropped more than 1.5% and 3.9% respectively over the week. CLRB's 24% weekly surge stands in clear contrast to a peer basket that was broadly flat to negative.
With borrow fully consumed, cost to borrow at a multi-year high, and earnings arriving Thursday morning, the dynamic to watch is whether the data catalyst and any forward guidance are sufficient to sustain the rally against a new and substantially larger short base.
See the live data behind this article on ORTEX.
Open CLRB on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
